Background {#Sec1}
==========

Management of rectal lesions, benign or malignant, evolved with the improvement of surgical tools and techniques. Total mesorectal excision (TME) and proctectomy remain the gold standard curative procedure \[[@CR1], [@CR2]\]. Based on evidence from multiple large randomized controlled trials (RCTs), minimally invasive TME operations using laparoscopy and robotic systems have been implemented and used widely across the globe.

Rectal lesions are increasingly detected with increased screening and awareness. This is connected to improved tools of diagnosis and management of these lesions.

Local excision (LE) of benign and early malignant rectal lesions was traditionally described to remove lesions within 8 cm from the anal verge \[[@CR3]\]. Higher lesions in the rectum rendered amenable for local excision using Transanal Endoscopic Microsurgery system described by Buess et al. more than three decades ago \[[@CR4]\]. It became more attractive for many reasons; such as better functional outcomes, less morbidity, faster recovery and avoidance of radical resections \[[@CR3]\].

Transanal Minimally Invasive Surgery (TAMIS) has revolutionized local excision of mid and high rectal lesions; benign or malignant. Since its introduction in 2009 by Atallah et al., this hybrid tool between single port laparoscopy and Transanal Endoscopic Microsurgery (TEM), has gained wider acceptance and popularity than TEM or the traditional Parks Transanal Excision (TAE), due to its superior surgical outcomes, shallow learning curve, and low cost, in addition to easier setup and more flexibility during the procedure \[[@CR5]\].

Methods {#Sec2}
=======

We retrospectively reviewed prospectively collected data on patients who underwent TAMIS for benign and early malignant rectal lesions between Jan 2015 and Sept 2019, at Hamad General Hospital, Doha, Qatar. All cases were discussed in colorectal multidisciplinary team (MDT) and the procedures were done by a single colorectal surgeon or under his direct guidance.

For malignant lesions, preoperative staging accomplished by CT scan and Rectal MRI. All cases were discussed in the tumor board before the procedure.

We assessed the following outcomes: feasibility, fragmentation of specimen, operative time, length of stay (LOS) post-operative complications, and margin negativity.

All patients underwent TAMIS in Lioyd-Davies position under general anesthesia (GA), except one patient who refused GA and had spinal anesthesia. We used GelPOINT path transanal access platform, and maintained pneumorectum to pressure of 15 mmHg with AirSeal system insufflator. As a standard operative preparation; all patients were positioned in Lloyd Davis position with a Bean Bag underneath the patient, in case laparoscopic access to the peritoneal cavity was to be required. All patients were given rectal phosphate enema approximately 4 h before the procedure. All patients received standard DVT prophylaxis. Prophylactic antibiotics were also administered at induction of anesthesia.

We used the GelPOINT path transanal access platform (Applied Medical, Rancho Santa Margarita, CA), AirSeal port (Conmed, NY, USA) to establish and sustain pneumorectum, and 30 degrees scope. We always approximate the defect after excision with V-Loc™ Vicryl (Medtronic, Minneapolis, MN, USA) The specimen then sent oriented to the histopathology department (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1**a** Colonoscopic appearance of rectal sessile polyp. **b** TAMIS view of the same polyp. **c** the polyp post TAMIS resection before closure. **d** resection site post closure

Results {#Sec3}
=======

Seventeen consecutive patients underwent TAMIS for benign and malignant rectal lesions, in the period between Jan 2015 and September 2019. The patients' population consisted of 6 women (34%) and 11 men (64%), with an average age of 52 years (28--88). Nine patients had an ASA score of 2, six patients of ASA score 3, and three patients with an ASA score of 1 (Table [1](#Tab1){ref-type="table"}). Table 1Patients demographicsPatients, n17 • Men11 (64%) • Women6 (34%)Age (years)52 (28--88)ASA Score • I3 • II9 • III5

The average length of stay (LOS) is 1.5 days (1--6 days). Eleven out of the eighteen patients discharged on day 1 post operatively. One patient stayed 6 days because of post-operative hypotension which was managed conservatively.

The average operative time was 74.17 min (20--180 min). The average distance of the lesion from the anal verge is 7.47 cm (3--18 cm). Eight patients (47%) had the lesion \> 7 cm from the anal verge.

Seven patients had different types of benign adenomas, five patients had proven adenocarcinoma, three patients had well-differentiated neuroendocrine tumors, one patient with hyperplastic polyp, and one patient had inflammatory polyp.

No fragmentation occurred or detected by histopathologic examination, except in a patient who had inflammatory polyp, where the lesion removed in two fragments. The average size of the excised lesions is 2.62 cm (1.2--7 cm). All resection margins were free, the nearest margin was 4 mm in a tubular adenoma specimen. Six patients had a discrepancy between the preoperative and the post-operative histopathology; one of the patients down-staged from polyp adenocarcinoma to polyp high-grade dysplasia. Another patient was diagnosed as moderately differentiated adenocarcinoma pre-operatively; which is located 5 cm from the anal verge, down-staged to benign lesion on final histopathology following TAMIS excision. Both of these patients were spared radical resections (Table [2](#Tab2){ref-type="table"}). Table 2Tumor characteristics and histopathology for locally excised lesionsDistance from anal verge, cm (range)7.41 (3--18)Tumor size, cm (range)**2.62** (1.2--7)Benign • Hyperplastic1 • Adenoma6 • Inflammatory1Cancer • T06 • T11 • T24Neuroendocrine Tumor3Discrepancy (pre-op to post-op) • Adenoma to Hyperplastic polyp1 • Hyperplastic polyp to adenoma1 • Adenoma to Polyp cancer1 • Polyp cancer to polyp high-grade dysplasia1 • Low-grade dysplasia to adenoma1 • Polyp high grade dysplasia to polyp cancer1 • Fragmentation1 • Positive marginsNone • Procedure-related complications (30 days)Bleeding not requiring transfusion (one patient)Intraoperative peritoneal perforation, repaired immediately (one patient)

In one patient, the peritoneum is entered during the excision of a tubular adenoma 10 cm from the anal verge. Laparoscopic closure of the peritoneum was achieved as well as transanal closure. The patient was discharged 2 days post operatively, with no complications.

There was one procedure-related complication during excision of a serrated adenoma located 10 cm from the anal verge, were the peritoneum was breached. Immediate laparoscopic repair was done, and the patient discharged home on day 2 post-operatively with no complications.

Another patient had minimal post-operative fresh bleeding per rectum which required no transfusion.

There were no other procedure-related immediate or 30-day complications in any of the other patients.

Discussion {#Sec4}
==========

Transanal Minimally Invasive Surgery (TAMIS) is a technique that is developed as a hybrid between Transanal Endoscopic Microsurgery (TEM) and laparoscopic surgery for resection of rectal lesions. Adoption of the technique has spread widely due to availability of the laparoscopic tools and insufflators and the single-site port, as well as the shallow learning curve, and most importantly the comparable safety and oncologic outcomes.

NCCN guidelines have defined the lesions which are appropriate for local excision using any system: mobile rectal tumors, less than 3 cm in size, occupying less than one-third of the circumference of the bowel, not extending beyond the submucosa, with well to moderate differentiation, and low-risk histopathological features. Transanal local excision is not appropriate for rectal tumors with high-risk characteristics, including lymphovascular invasion, perineural invasion, and mucinous components \[[@CR1]\].

We have demonstrated a congruent result of safety and oncologic outcomes using TAMIS compared to the existing literature and case series \[[@CR6]--[@CR8]\]. All our malignant lesion resections as well as NET resections were margin negative. The reported positive margin in a recent large series of 200 patients was 7% \[[@CR9]\], and up to 2 out of 3 NET resections in some series \[[@CR10]\] (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Table 3Characteristics of individual casesNoAge group / SexLocation (cm)Pre-operative HPIndicationTumor size (cm)Post-operative HPNeed for further management135--45/ S27Tubulovillous adenoma with low grade dysplasiaTreatment2.8 × 2.5Tubulovillous adenomaNone245--55/ S218Serrated adenoma with low grade dysplasiaTreatment1.5 × 0.5hyperplastic polypNone355--65/ S15Moderately differentiated adenocarcinomaTreatment2.2 × 1.7pT0Nx adenocarcinomaNone455--65/ S210Serrated adenomaTreatment2.5 × 2.2Serrated adenomaNone555--65/ S210Hyperplastic polypTreatment2.5 × 2.2Tubular adenomaNone625--35/ S14Well differentiated NETTreatment2.7 × 2.2 cm (tumor 4 mm)Well differentiated NETNone755--65/ S110Tubulovillous adenomaTreatment2.3 (cancer 2 mm)Polyp Moderately differentiated adenocarcinoma (Haggit's 1)None885--95/ S13Moderately differentiated adenocarcinoma (cT2 / early T3 N0 M0)Treatment3.9 × 2.3Moderately differentiated adenocarcinoma (pT2)None955--65/ S28Well differentiated NETTreatment1.2 × 0.6 mmWell differentiated NETNone1035--45/ S14Moderately differentiated invasive adenocarcinoma, arising in a tubular adenoma with high-grade dysplasiaTreatment1.5 × 0.7Tubular adenoma with high-grade dysplasiaNone1165--75/ S23Villous adenoma with at least high-grade dysplasia and suspicions cancerTreatment3 × 2 × 0.5Moderately differentiated adenocarcinoma cT1N0M0None1235--45/ S15Well differentiated NETTreatment2.3 × 1.7 × 0.7 (nodule 0.8 cm)Well differentiated NETNone1325--35/ S19Low grade dysplasiaTreatment7 × 5 × 4 cmVillous adenomaNone1445--55/ S15Tubulovillous adenoma with focal high-grade dysplasiaTreatment3 × 2.5 × 1.5Tubulovillous adenomaNone1535--45/ S110Well differentiated adenocarcinoma on tubulovillous adenoma (incomplete colonoscopic removal)Treatment4.5 × 3.6 × 2Residual well differentiated adenocarcinoma on tubulovillous adenoma (SM3)None1645--55/ S15NoneDiagnostic and treatment2.7 × 1.8 × 0.8 cm and 2.8 × 2 × 0.4 cmbenign inflammatory cloacogenic polyp/ mucosal prolapse.None1755--65/ S110Tubulovillous adenoma with focal high-grade dysplasiaTreatment2.5 × 1.7 × 1.8 cmModerately differentiated invasive adenocarcinoma with mucinous component in a background of tubulovillous adenoma with focal high grade dysplasia. Kikuchi SM2NoneTable 4Characteristics of malignant lesions excised using TAMISNoAge group/sexLocation (cm)Pre-operative HPColonoscopy findingsMRI findingsIndicationTumor size (cm)Post-operative HPNeed for further management155--65 / S15Moderately differentiated adenocarcinoma (reaching inked margin)Sessile polyp in the rectum (snared)No gross lesion foundTreatment2.2 × 1.7pT0, no residual; tumorNone255--65 / S110Tubulovillous adenomaFlat polypLesion in mid-rectum confined to muscularis propriaTreatment2.3 (cancer 2 mm)Polyp Moderately differentiated adenocarcinoma (Haggit's 1)None385--95 / S13Moderately differentiated adenocarcinoma (cT2 / early T3 N0 M0)Ulceroproliferative lesion in the rectumNo MRI. EUS showed T2 / early T3Treatment, patient unfit for radical resection3.9 × 2.3Moderately differentiated adenocarcinoma (pT2)None435--45 / S14Moderately differentiated invasive adenocarcinoma, arising in a tubular adenoma with high-grade dysplasia2 cm rectal lesion (infiltrating the mucosa)Definite polypoidal lesion at the lower rectum T1/T2 with thickened CRMTreatment1.5 × 0.7Tubular adenoma with high-grade dysplasiaNone575--85 / S23Villous adenoma with at least high-grade dysplasia and suspicions cancerRectal mass with query malignant featuresNo MRI. EUS: T3 lesionTreatment3 × 2 × 0.5Moderately differentiated adenocarcinoma cT1N0M0None635--45 / S110Well differentiated adenocarcinoma on tubulovillous adenoma (incomplete colonoscopic removal)Large rectal polyp 10 cm from anal verge, with broad base. Removed incompletely in fragmentsLesion in the upper rectum could not be clearly appreciated because of metallic clips placed after polypectomyTreatment4.5 × 3.6 × 2Residual well differentiated adenocarcinoma on tubulovillous adenoma (SM3)None755--65 / S110Tubulovillous adenoma with focal high-grade dysplasiaSessile polypoid lesion with central depression, about 1.5 cm in size, at 10 cm from anal vergeRight posterolateral polypoidal wall thickening measuring approximately 15 mm, with central hyperintensity; no significant diffusion restriction or hyperenhancement. No extension beyond the muscularis.Treatment2.5 × 1.7 × 1.8 cmModerately differentiated invasive adenocarcinoma with mucinous component in a background of tubulovillous adenoma with focal high grade dysplasia. Kikuchi SM2None

Our series showed that despite the fact that a relatively small number of patients dispersed over a period of nearly 5 years, the surgical outcomes, operative time, and quality of specimens did not compare unfavorably. One of our patients had a lesion 10 cm from anal verge with malignant features of T3 tumor by MRI, which was difficult to diagnose using colonoscopy due to superficial biopsy. TAMIS used in this patient to obtain adequate biopsies, which confirmed adenocarcinoma enabling the patient to receive neoadjuvant chemoradiotherapy.

Conclusions {#Sec5}
===========

TAMIS procedure is feasible and safe even in a relatively low-volume colorectal unit. Using this tool, many patients can avoid unnecessary radical surgery. Therefore, we believe that TAMIS should form part of every specialized colorectal service repertoire. To our knowledge, this is the largest series in the gulf region.

TAMIS

:   Transanal Minimally Invasive Surgery

TEM

:   Transanal endoscopic microsurgery

TAE

:   Transanal excision

LE

:   Local excision

MDT

:   Multidisciplinary team

NET

:   Neuroendocrine tumor

LOS

:   Length of stay

ASA

:   American College of Anesthesiologists Physical Status Classification

RCT

:   Randomized controlled trial

CT scan

:   Computerized tomography scan

MRI

:   Magnetic resonance imaging

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The publication of this article was funded by the Qatar National Library.

**AGA** Data acquisition and analysis, drafting the manuscript, **AA** Data analysis and critical revision of manuscript. **MA** Data acquisition and critical revision of manuscript. **MK**: Study concept and design, data analysis, writing and revision of the manuscript. All authors have read and approved the manuscript.

The processing fees for publication of this article was funded by the Qatar National Library.

All data generated or analysed during this study are included in this published article.

Not applicable.

Not applicable.

The authors declare that they have no competing interests.
